Thursday, October 31, 2013
Gilead Alberta, a fully integrated research and manufacturing facility of Gilead Sciences Canada, has announced a $47 million expansion of its research and manufacturing facility in Edmonton, Alberta. The expansion will create more than 80 full-time positions at Gilead Alberta and increase the size of the facility by 45,000 square feet to create new laboratory and research space.
PGXL Technologies, a global provider in the clinical application of pharmacogenetic and molecular diagnostic testing for personalized medicine, has received a contract to help the National Cancer Institute further the science of early cancer diagnosis through the detection of circulating tumor cells (CTCs). The $300,000 contract was one of four awarded.
Algorithme Pharma, a provider focused on early stage clinical research, has formed an alliance with the University of Montreal Hospital Research Center (CRCHUM), allowing for access to an expanded pool of patients and a new research complex for conducting complex early stage clinical trials.
Langland, a healthcare advertising agency, has launched “Speak Out, But Speak Smart,” an online communication guide for clinical trial participants. Developed in collaboration with CISCRP, the web site encourages discussions while showing how sharing certain information can have unforeseen consequences: for example, psychosomatic side effects resulting from the knowledge of another participant’s adverse event.
Stemline Therapeutics, a clinical-stage biopharmaceutical company developing novel oncology therapeutics, and The Leukemia & Lymphoma Society (LLS) are collaborating to accelerate the development of SL-401 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological disorder with both leukemic and lymphomatous characteristics.